Lim S H, Hale G, Marcus R E, Waldmann H, Baglin T P
Department of Haematology, Addenbrooke's Hospital, Cambridge.
Br J Haematol. 1993 Jul;84(3):542-4. doi: 10.1111/j.1365-2141.1993.tb03117.x.
Six patients with autoimmune thrombocytopenic purpura (three of whom had CLL/NHL and one previous Hodgkin's disease) refractory to conventional therapy were treated with an antilymphocyte monoclonal antibody directed at CDw52 (CAMPATH-1). We observed response in four of the five evaluable patients; in three patients the response has lasted more than 4-9 months. However, response did not occur in most cases until 4-6 weeks after the commencement of the antibody therapy, suggesting that the mechanism of action is probably that of immune modulation.
六名对传统治疗无效的自身免疫性血小板减少性紫癜患者（其中三名患有慢性淋巴细胞白血病/非霍奇金淋巴瘤，一名曾患霍奇金病）接受了一种针对CDw52的抗淋巴细胞单克隆抗体（CAMPATH-1）治疗。在五名可评估的患者中，我们观察到四名有反应；三名患者的反应持续了4至9个月以上。然而，大多数情况下，直到抗体治疗开始后4至6周才出现反应，这表明其作用机制可能是免疫调节。
